Has your health system prepared for HRSA’s forthcoming 340B Rebate Model Pilot Program, scheduled to begin January 1, 2026? We have. At the bottom of this post, you’ll find a detailed overview of exactly how our 340B team has prepared to help the 340B health systems we serve — including a short-term loan program we’ll … Read More
How can this unprecedented manufacturer restriction generate the company, OR patients, a net benefit? It would not be an exaggeration to say that Bausch Health (BHC) sent shockwaves through much of the healthcare industry in declaring its intention to cease participation in what it deemed two “optional” Federal drug pricing programs — the Medicaid Drug … Read More
Before we begin, we’re going to be honest with you. A significant component of VytlOne’s business is guiding 340B health systems through the process of building, accrediting, funding, launching and managing on-campus specialty pharmacies. Many times in this space, we’ve maintained that every 340B hospital should consider owning a specialty pharmacy. We’re currently in the … Read More
Maximizing pharmacy’s role in your hospital’s revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. The average 340B-eligible hospital loses a substantial amount of money due to drug manufacturer restrictions on the program. Recent estimates indicate that hospitals and clinics collectively … Read More
POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B scripts Retrieving 340B eligible-script data Establishing communication lines between internal and external 340B teams Why specialized software is essential for successful 340B programs The central problem with most 340B programs’ data Why 340B software … Read More
Far too many 340B hospitals overlook pharmacy’s overall potential in their health systems’ revenue cycles. Below is a graphic overview of VytlOne’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to … Read More
POST OUTLINE 1) What we’ve learned. What it means for your 340B program. Overview of VytlOne 340B Team experience and successes Dealing with frequent, unexpected changes 2) Potential 340B developments for 2024 National legislation prospects State regulatory changes 3) Legislative & court updates Bill introduced into House Of Representatives Supreme Court overturns 340B restriction cuts … Read More
Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More
Below is a graphic overview of VytlOne’s integrated approach to optimizing a health system’s pharmacy services, savings and revenue. In 340B support alone, we’ve generated over $500 million for the hospitals we serve — revenue those systems have used to positively impact the quality and scope of patient care they offer, in countless ways. Why … Read More
It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More
